ReviewCureus2026
Comparative Efficacy of Palonosetron-Dexamethasone Versus Granisetron-Dexamethasone for Prevention of Postoperative Nausea and Vomiting: A Review With Focus on Otologic Surgeries.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative nausea and vomiting (PONV) remain one of the most distressing and consequential complications in perioperative care, with a particularly high incidence in otologic surgeries, where vomiting can jeopardize graft stability and hearing outcomes. This review provides a focused, evidence-based evaluation of the comparative efficacy of palonosetron-dexamethasone and granisetron-dexamethasone combinations in preventing PONV, integrating pharmacologic insights with procedure-specific clinical implications. Drawing upon studies published between 2015 and 2025, it highlights the superior and sustained efficacy of palonosetron, a second-generation serotonin (5-hydroxytryptamine type 3; 5-HT₃) receptor antagonist, due to its longer half-life, allosteric receptor binding, and enhanced pharmacodynamic stability. The synergistic benefit of combining a 5-HT₃ receptor antagonist with dexamethasone, a corticosteroid with anti-inflammatory and central inhibitory properties, is emphasized, demonstrating improved control of both early and delayed PONV with minimal adverse effects. Moreover, the review contextualizes these findings within the unique challenges of otologic procedures and discusses their safety, cost-effectiveness, and clinical applicability. By bridging pharmacologic evidence with surgical realities, this review underscores the need for procedure-specific, long-acting antiemetic strategies and advocates for multicentric, cost-conscious research to refine prophylactic protocols. Ultimately, it offers a novel synthesis that advances PONV management in otologic surgery through the integration of clinical efficacy, patient safety, and economic prudence. The evidence supports palonosetron-dexamethasone as the more effective and sustained prophylactic regimen compared with granisetron-dexamethasone, particularly for delayed PONV (6-48 h) in otologic surgeries. Palonosetron-based dual therapy should be preferred in high-risk middle ear procedures where postoperative vomiting may compromise graft integrity, while granisetron-dexamethasone remains a reasonable lower-cost option for shorter or lower-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.